UK Biotech Thalia Therapeutics Secures €3.1 Million to Acquire US-Based Sanmirna and Expand RNA Pipeline
Thalia Therapeutics, a UK-based biotech company, raised €3.1 million and acquired Sanmirna Therapeutics, a US-based clinical-stage biotech, to advance its RNA therapeutics pipeline in oncology and cardiovascular disease. The acquisition includes miRisten, a clinical-stage microRNA therapeutic for Acute Myeloid Leukaemia (AML).